Menu
Home
People
Places
Arts
History
Plants & Animals
Science
Life & Culture
Technology
Reference.org
Zosurabalpin
open-in-new
<p>Zosurabalpin (RG6006, Abx-MCP, Ro7223280) is an experimental <a href="/facts/Antibiotic/sF1kIfxg">antibiotic</a> developed in a collaboration between the pharmaceutical company <a href="/facts/Roche/hHVcLCXb">Roche</a> and scientists from <a href="/facts/Harvard_University/Lhy9L1cx">Harvard University</a>, for the treatment of <a href="/facts/Carbapenem/ydKuuwfQ">carbapenem</a>-resistant <i><a href="/facts/Acinetobacter_baumannii/LV2FN4uD">Acinetobacter baumannii</a></i> (CRAB). It targets a <a href="/facts/Lipopolysaccharide/Ch967TXw">lipopolysaccharide</a> transporter. It works by recognizing a composite binding site made up of both the Lpt transporter and its LPS substrate. The chemical family to which it belongs was first disclosed in 2019, but the particular structure of RG6006 remained confidential until publication of the testing results in 2023. </p>